Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001059968 | SCV001224624 | uncertain significance | DOCK2 deficiency | 2021-06-17 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with DOCK2-related conditions. This variant is present in population databases (rs768935540, ExAC 0.003%). This sequence change replaces methionine with leucine at codon 1376 of the DOCK2 protein (p.Met1376Leu). The methionine residue is weakly conserved and there is a small physicochemical difference between methionine and leucine. |
| Ambry Genetics | RCV004031905 | SCV004860256 | uncertain significance | Inborn genetic diseases | 2024-02-06 | criteria provided, single submitter | clinical testing | The c.4126A>T (p.M1376L) alteration is located in exon 41 (coding exon 41) of the DOCK2 gene. This alteration results from a A to T substitution at nucleotide position 4126, causing the methionine (M) at amino acid position 1376 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |